// App-Quantinova.ai

3646 : Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

Researchers

Presenter

  • Julie E. Chang

Principal Investigators

  • Bruce D. Cheson

  • Peter Martin

  • Robert Rifkin

  • Solomon Hamburg

  • Ruben Reyes

  • Ai-Min Hui

  • Jiang Yu

  • Neeraj Gupta

  • Alessandra Di Bacco

  • Yaping Shou

Medical Centers

  • Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI

  • Division of Hematology and Department of Oncology, Jewish General Hospital, Montreal, QC, Canada

Locations

  • United States

  • Canada

Companies

  • Millennium Pharmaceu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Peripheral T-cell lymphoma

  • Peripheral neuropathy

  • Follicular lymphoma

  • Mycosis fungoides

  • Hodgkin's Lymphoma

  • Thrombocytopenia

  • B cell lymphomas

  • T-cell lymphoma

  • Renal insufficiency

  • Neutropenia

  • Lymphomas

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Bortezomib

  • Ixazomib

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • I

Study Id's

  • NCT00893464

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved